Journal
BREAST CANCER RESEARCH
Volume 2, Issue 2, Pages 125-132Publisher
BMC
DOI: 10.1186/bcr44
Keywords
transforming growth factor (TGF)-beta; TGF-beta receptors; epithelial-to-mesenchymal transition; angiogenesis
Categories
Funding
- NCI NIH HHS [R01 CA62212, CA68485] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA062212, P30CA068485] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The transforming growth factor (TGF)-betas are potent growth inhibitors of normal epithelial cells. In established tumor cell systems, however, the preponderant experimental evidence suggests that TGF-betas can foster tumor-host interactions that indirectly support the viability and/or progression of cancer cells. The timing of this 'TGF-beta switch' during the progressive transformation of epithelial cells is not clear. More recent evidence also suggests that autocrine TGF-beta signaling is operative in some tumor cells, and can also contribute to tumor invasiveness and metastases independent of an effect on nontumor cells. The dissociation of antiproliferative and matrix associated effects of autocrine TGF-beta signaling at a transcriptional level provides for a mechanism(s) by which cancer cells can selectively use this signaling pathway for tumor progression. Data in support of the cellular and molecular mechanisms by which TGF-beta signaling can accelerate the natural history of tumors will be reviewed in this section.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available